|
Jul 31
|
REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights
|
|
Jul 24
|
REGENXBIO Inc. (RGNX): A Bull Case Theory
|
|
Jul 18
|
REGENXBIO Inc. (NASDAQ:RGNX) is largely controlled by institutional shareholders who own 67% of the company
|
|
Jul 10
|
REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy
|
|
Jun 19
|
Gene Therapy Has Lost Support on Wall Street. There’s Still Hope for Big Cures.
|
|
Jun 5
|
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
|
|
Jun 2
|
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202
|
|
Apr 1
|
Biotech stocks slide as Marks resignation seen being negative for sector
|
|
Mar 14
|
Q4 2024 Regenxbio Inc Earnings Call
|
|
Mar 14
|
Regenxbio Inc (RGNX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Resilience
|
|
Mar 13
|
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
|
|
Mar 13
|
Regenxbio: Q4 Earnings Snapshot
|
|
Mar 13
|
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
|
|
Mar 10
|
REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
|
|
Feb 20
|
Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth
|
|
Feb 11
|
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
|
|
Feb 10
|
Wall Street Analysts Think Regenxbio (RGNX) Could Surge 333.01%: Read This Before Placing a Bet
|
|
Sep 3
|
RegenxBio touts positive data for rare disease drug RGX-121
|
|
Sep 3
|
REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
|
|
Jul 25
|
REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights
|